Amanote Research
Register
Sign In
Cost Effectiveness of Ivacaftor and Lumacaftor Combination for the Treatment of Patients With Cystic Fibrosis in the United States
Value in Health
- United Kingdom
doi 10.1016/j.jval.2016.09.493
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
November 1, 2016
Authors
D Sharma
S Xing
Y Hung
RN Caskey
ML Dowell
DR Touchette
Publisher
Elsevier BV
Related search
Effect of One-Year Lumacaftor–ivacaftor Treatment on Glucose Tolerance Abnormalities in Cystic Fibrosis Patients
Journal of Cystic Fibrosis
Child Health
Pulmonary
Pediatrics
Perinatology
Respiratory Medicine
Frequency and Costs of Pulmonary Exacerbations in Patients With Cystic Fibrosis in the United States
Current Medical Research and Opinion
Medicine
Bridging for Lung Transplantation With Lumacaftor/Ivacaftor
Breathe
Pulmonary
Respiratory Medicine
Monotherapy Versus Combination Therapy for the Treatment of Pseudomonas Aeruginosa in Cystic Fibrosis Patients
Journal of Antibiotics Research
Cost-Effectiveness of Carrier Screening for Cystic Fibrosis in Australia
Journal of Cystic Fibrosis
Child Health
Pulmonary
Pediatrics
Perinatology
Respiratory Medicine
Long-Term Computed Tomographic Changes in Cystic Fibrosis Patients Treated With Ivacaftor
European Respiratory Journal
Medicine
Pulmonary
Respiratory Medicine
Cost-Effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients With Heavily Pretreated Relapsed–refractory Multiple Myeloma in the United States
Clinical Therapeutics
Pharmacology
Pss26 - Cost Effectiveness of Ocriplasmin for Treatment of Symptomatic Vitreomacular Adhesion in the United States
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
The Impact of 12 Months Treatment With Ivacaftor on Scottish Paediatric Patients With Cystic Fibrosis With the G551D Mutation: A Review: Table 1
Archives of Disease in Childhood
Child Health
Pediatrics
Perinatology
